New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented ...
Sep 6, 2025
0
25
